Trial · NCT02669862

A Study of A-101 Solution in Subjects With Common Warts.

NCT02669862, Phase 2, Completed, Aclaris Therapeutics, Inc.; results first posted 2018-12-07

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. A Study of A-101 Solution in Subjects With Common Warts. Trials, record NCT02669862. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02669862

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: A Study of A-101 Solution in Subjects With Common Warts.
NCT number: NCT02669862
Status: Completed
Phases: Phase 2
Enrollment: 98 participants, actual
Lead sponsor: Aclaris Therapeutics, Inc.
Conditions: Common Warts
Interventions: A-101 Solution 40, A-101 Solution 45, Vehicle Solution
First posted: 2016-02-01
Last updated: 2018-12-07
Results first posted: 2018-12-07

Source ClinicalTrials.gov

Registered outcomes3

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Efficacy Based on Mean Change in Physician Wart Assessment Over Time	57 Days	The primary effectiveness will consist of the mean change from Visit 2 to Visit 10 in Physician Wart Assessment (PWA) performed using Analysis of Covariance (ANCOVA) with Visit 2 PWA as the covariate. Physician Wart Analysis is a measurement scale from 0 to 3 that evaluates the wart with 0 being clear and 3 being clinically diagnosable wart that is raised, with an obviously rough surface.
Secondary	Durability of Response - Percentage of Participants That Were Clear at Visit 10 That Are Still Clear at Visit 13	visit 10 to visit 13	Percentage of subjects whose target wart was clear at Visit 10 and who remained clear at Visit 13 for active treatment groups
Secondary	PWA Responder	Day 57	The percentage of participants who were responders with the target wart judged to be clear (PWA = 0) at Visit 10.

Source ClinicalTrials.gov

Outcomes3

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Efficacy Based on Mean Change in Physician Wart Assessment Over Time	57 Days	Number of participants analyzed is the number of participants completing the protocol through visit 10.	units on a scale	MEAN
SECONDARY	Durability of Response - Percentage of Participants That Were Clear at Visit 10 That Are Still Clear at Visit 13	visit 10 to visit 13	Only the number of participants clear at visit 10 are compared to the number of participants clear at visit 13 to get the percentage clear for active treatment groups only.	percentage participants	NUMBER
SECONDARY	PWA Responder	Day 57	PP population = participants completing protocol to visit 10	percentage of responders	NUMBER

Source ClinicalTrials.gov

Results by group8

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Efficacy Based on Mean Change in Physician Wart Assessment Over Time	A-101 Solution 40	-0.38	Standard Deviation 0.75	units on a scale
Efficacy Based on Mean Change in Physician Wart Assessment Over Time	A-101 Solution 45	-1.00	Standard Deviation 0.97	units on a scale
Efficacy Based on Mean Change in Physician Wart Assessment Over Time	Vehicle Solution	-0.44	Standard Deviation 0.85	units on a scale
Durability of Response - Percentage of Participants That Were Clear at Visit 10 That Are Still Clear at Visit 13	A-101 Solution 40	100		percentage participants
Durability of Response - Percentage of Participants That Were Clear at Visit 10 That Are Still Clear at Visit 13	A-101 Solution 45	87.50	95% Confidence Interval 64.58 to 99.99	percentage participants
PWA Responder	A-101 Solution 40	3.13		percentage of responders
PWA Responder	A-101 Solution 45	25.81		percentage of responders
PWA Responder	Vehicle Solution	3.70		percentage of responders

Source ClinicalTrials.gov

Participant flow9

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	A-101 Solution 40	33
Overall Study	STARTED	A-101 Solution 45	34
Overall Study	STARTED	Vehicle Solution	31
Overall Study	COMPLETED	A-101 Solution 40	31
Overall Study	COMPLETED	A-101 Solution 45	29
Overall Study	COMPLETED	Vehicle Solution	26
Overall Study	NOT COMPLETED	A-101 Solution 40	2
Overall Study	NOT COMPLETED	A-101 Solution 45	5
Overall Study	NOT COMPLETED	Vehicle Solution	5

Source ClinicalTrials.gov

Adverse events18

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Application site pain	General disorders	A-101 Solution 40	2	33	2
other	Application site pain	General disorders	A-101 Solution 45	0	34	0
other	Application site pain	General disorders	Vehicle Solution	0	31	0
other	Seasonal allergy	Immune system disorders	A-101 Solution 40	1	33	1
other	Seasonal allergy	Immune system disorders	A-101 Solution 45	3	34	3
other	Seasonal allergy	Immune system disorders	Vehicle Solution	2	31	2
other	Upper respiratory tract infection	Infections and infestations	A-101 Solution 40	4	33	4
other	Upper respiratory tract infection	Infections and infestations	A-101 Solution 45	0	34	0
other	Upper respiratory tract infection	Infections and infestations	Vehicle Solution	2	31	2
other	Headache	Nervous system disorders	A-101 Solution 40	1	33	1

1 to 10 of 18Source ClinicalTrials.gov

See all 18 adverse events

Adverse event totals9

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	A-101 Solution 40	0	33
Total, all-cause mortality	A-101 Solution 45	0	34
Total, all-cause mortality	Vehicle Solution	0	31
Total, other adverse events	A-101 Solution 40	8	33
Total, other adverse events	A-101 Solution 45	6	34
Total, other adverse events	Vehicle Solution	10	31
Total, serious adverse events	A-101 Solution 40	0	33
Total, serious adverse events	A-101 Solution 45	0	34
Total, serious adverse events	Vehicle Solution	0	31

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT02669862

GET https://conductscience.org/api/trials/v1/NCT02669862/registered

API reference For AI assistants